Author of

• 11001

  +

  P1.24 - Poster Session 1 - Clinical Care (ID 146)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11046

    +

    P1.24-045 - A case with long term survival following received paclitaxel as fourth line chemotherapy in refractory-relapsed small-cell lung carcinoma. (On behalf of NT-TOG group) (ID 3096)

    09:30 - 09:30  |  Author(s): B. Chewaskulyong
    • Abstract

    Background
    Small-cell lung cancer constitutes 10-15% of lung cancer cases. Although it is sensitive to chemotherapy and radiotherapy, but usually relapsed and recurred with median survival time less than 6 months after second line therapy. Paclitaxel monotherapy had been reported its efficacy with minimal toxicity in relapsed small-cell lung cancer treatment. This presenting case demonstrated activity of paclitaxel in relapsed-refractory small-cell lung cancer in fourth line of treatment.

    Methods
    This is the case report of paclitaxel monoherapy in fourth line of refractory -relapsed small-cell lung cancer treatment.

    Results
    A 72-year-old woman with a history of ex-smoker and hypertension presented in September 2007 with weight loss and left- sided chest pain.On physical examination revealed bronchial breathsound at left lung .Computed tomography scan of the thorax showed 5.7 * 4.5 cm mass at left hilar region and occlude left middle part of bronchus. Bronchoscopic biopsy was done and histology showed small-cell lung carcinoma. Staging work up was performed and resulted was limited stage disease. The patients was admininistered chemotherapy with standard cisplatin and etoposide regimen. Concurrent chemoradiotherapy was started on 3rd cycle of chemotherapy . She received first line chemotheapy with total 5 cycles of chemotherapy with good clinical response. Chest imaging showed nearly partial response. Before 6th cycle of chemotherapy she developed relapsed small-cell lung carcinoma and was treated with cisplatin plus irinotecan as second line therapy for 2 cycles and third line with cyclophosphamide/adriamycin/vincristine regimen for 1 cycle with no response and had worse lung symptoms . Fourth line chemotherapy was administered with paclitaxel 175 mg/m2 every 3 weeks for 4 cycle between April and July 2008 . After second cycle of paclitaxel her symptoms and chest imaging were improved. After 4 cycle of paclitaxel monotherapy she was evaluated as stable disease and had long survival since 2008 until now with symptom- free and no relapsed of disease for more than 5 years.She had minimal toxicity from paclitaxel with only mild neuropathy.

    Conclusion
    In conclusion this case demonstrated that paclitaxel still had benefit with long-term survival and minimal toxicity eventhough in the fourth line therapy of refractory-relapsed small-cell lung cancer.

• 12853

  +

  P3.24 - Poster Session 3 - Supportive Care (ID 160)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12883

    +

    P3.24-030 - Activity and tolerability of carboplatin and gemcitabine in first-line treatment of elderly Thai patients with advanced non-small cell lung cancer (NSCLC). (ID 1930)

    09:30 - 09:30  |  Author(s): B. Chewaskulyong
    • Abstract

    Background
    Despite the rising incidence of NSCLC in the elderly population in Thailand, a well defined chemotherapy regimen for these patients has not been reported. This study examines the toxicity and activity of doublet carboplatin and gemcitabine in Thai patients with advanced NSCLC.

    Methods
    Chemotherapy-naive patients with histological/cytological proven advanced NSCLC, aged > 65 years, ECOG 0-1 and adequate organs function were treated with carboplatin (AUC5) and gemcitabine (1000 mg/m[2] in a 30-min infusion D1, 8) every 21 day for maximum 6 cycles. The primary endpoint was objective tumor response rate and tolerability to this regimen.

    Results
    From November 2011 to February 2013, 30 patients were evaluated. Median age was 73 years (range 65-83), 70% were male, 70% were smoker and all patients had PS 0 (30%) or PS 1 (70%). Stage IIIb disease in 13% patients and stage IV in 87% patients. Non-squamous cell carcinoma in 73% patients (adenocarcinoma 66%, large cell carcinoma 3.5%, other 3.5%) and squamous cell carcinoma in 27% patients. The median number of cycle was 4 (range 2-6). Among the 29 patients with measurable disease, there were 7 PR, 15 SD and 7 PD (response rate 24%). The most common hematologic toxicity was grade 3 anemia in 20% and grade 3 leukopenia in 10%. Febrile neutropenia occurred in 3%. No treatment related death was observed. Non-hematologic toxicity was generally mild and grade 1 fatigue occurred in 30%. The median progression free survival was 4.9 months (range 2-16).

    Conclusion
    The doublets carboplatin and gemcitabine could be a valuable treatment option in elderly Thai patients. The activity and safety observed in this report is within the range of data reported for doublet chemotherapy regimen in the elderly patient with NSCLC.